Cantor Fitzgerald analyst Charles Duncan raised the firm’s price target on Intra-Cellular to $98 from $90 and keeps an Overweight rating on the shares. Intra-Cellular reported Q2 CAPLYTA net revenues of $110M, above the firm’s estimate of $105M, and the firm believes CAPLYTA is continuing to demonstrate notable top-line performance driven by its increasingly clear and differentiated clinical profile, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ITCI:
- Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference
- Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
- Intra-Cellular sees FY23 CAPLYTA net sales $445M-$465M
- Intra-Cellular reports Q2 EPS (45c), consensus (59c)
- Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast